The Zhitong Finance App learned that UBS released a research report stating that it initially gave Fu Hong Hanlin (02696.HK) a “buy” rating, with a target price of HK$82.8. The bank believes that Fuhong Hanlin, as a comprehensive biopharmaceutical company, has undervalued the long-term growth potential of its global biosimilar business base and innovation pipeline in terms of valuation.

The Zhitong Finance App learned that UBS released a research report stating that it initially gave Fu Hong Hanlin (02696.HK) a “buy” rating, with a target price of HK$82.8. The bank believes that Fuhong Hanlin, as a comprehensive biopharmaceutical company, has undervalued the long-term growth potential of its global biosimilar business base and innovation pipeline in terms of valuation.